Treatment of aregeneratoric anemia following an ABO-incompatible allogeneic peripheral blood stem cell transplantation: a case report.
Aregeneratoric anemia (AA) occurs rarely after ABO-incompatible allogeneic peripheral blood stem cell transplantation (alloPBSCT), and its management is generally difficult. Here, we present a 31-year-old white man with myelodysplastic syndrome who developed AA after receiving stem cells from his human leukocyte antigen (HLA) identical, but ABO-incompatible sibling. Because his anti-A antibody titers were high, therapy with conventional doses of erythropoietin and prednisolone failed to treat the AA. Following 8 cycles of plasma exchange and higher doses of erythropoietin and prednisolone as well as danazol administration, anti-A titers decreased, and his anemia improved significantly. In conclusion, to treat and obtain a low titer of antibodies in a patient with AA following an ABO-incompatible alloPBSCT, higher doses of erythopoietin and corticosteroids associated with plasma exchange have to be used.
Ustün
C
C
Department of Hematology/Oncology, Ibn-i Sina Hospital, Medical School, Ankara University, Turkey. ustun@dialup.ankara.edu.tr
Celebi
H
H
Arat
M
M
Ozcan
M
M
Dilek
I
I
Gürman
G
G
Demirer
T
T
Ilhan
O
O
Keskin
R
R
Koç
H
H
D000017:ABO Blood-Group System; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001787:Blood Group Incompatibility; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D010951:Plasma Exchange; D011239:Prednisolone / Q000627:therapeutic use; D012010:Red-Cell Aplasia, Pure / Q000628:therapy*
D000017:ABO Blood-Group System; D000893:Anti-Inflammatory Agents; D011239:Prednisolone